The nomenclature of the blond capuchin, Cebus flavius (Schreber, 1799) (Mammalia, Primates, Cebidae)

Zijlstra, Jelle S. (2020): The nomenclature of the blond capuchin, Cebus flavius (Schreber, 1799) (Mammalia, Primates, Cebidae). Zootaxa 4820 (2): 398-400, DOI: https://doi.org/10.11646/zootaxa.4820.2.1

FIGURE 2 in A new oryzomyine (Rodentia: Sigmodontinae) from the Quaternary of Curaçao (West Indies)

FIGURE 2. Left lower dentition of Oryzomys gorgasi (LACM 96090)

A new oryzomyine (Rodentia: Sigmodontinae) from the Quaternary of Curaçao (West Indies)

Zijlstra, Jelle S. (2012): A new oryzomyine (Rodentia: Sigmodontinae) from the Quaternary of Curaçao (West Indies). Zootaxa 3534: 61-68, DOI: 10.5281/zenodo.28279

The westernmost tarsier: A new genus and species from the Miocene of Pakistan

As the closest living sister group of anthropoids, tarsiers (Family Tarsiidae) are an important group in primate evolution. However, their fossil record is poor: only four species have been described, two from the Eocene of China and two from the Miocene of Thailand. All are from outside the range of the living species, which occur only on islands off Southeast Asia. Here, we describe a new fossil tarsier from Pakistan, a significant range extension. This record consists of two lower molars, an upper molar, and a lower premolar found in the Miocene Manchar Formation (~18-16Ma [millions of years ago]) of Sindh Province, southern Pakistan. The Pakistani tarsier is morphologically distinct from all living and fossil tarsiers, but most similar to the middle Miocene Thai species Tarsius thailandicus. Though living tarsiers have traditionally been classified in a single genus, a recent revision proposed a division into three genera, which is strongly supported by molecular data. The Pakistani species is not referable to any of these genera, and we create for it and T.thailandicus a new tarsiid genus. This discovery broadens our understanding of the geographic range and morphological diversity of Miocene tarsiers and helps to put the living tarsiers into their evolutionary context. © 2013 Elsevier Ltd

The westernmost tarsier: A new genus and species from the Miocene of Pakistan

As the closest living sister group of anthropoids, tarsiers (Family Tarsiidae) are an important group in primate evolution. However, their fossil record is poor: only four species have been described, two from the Eocene of China and two from the Miocene of Thailand. All are from outside the range of the living species, which occur only on islands off Southeast Asia. Here, we describe a new fossil tarsier from Pakistan, a significant range extension. This record consists of two lower molars, an upper molar, and a lower premolar found in the Miocene Manchar Formation (~18-16Ma [millions of years ago]) of Sindh Province, southern Pakistan. The Pakistani tarsier is morphologically distinct from all living and fossil tarsiers, but most similar to the middle Miocene Thai species Tarsius thailandicus. Though living tarsiers have traditionally been classified in a single genus, a recent revision proposed a division into three genera, which is strongly supported by molecular data. The Pakistani species is not referable to any of these genera, and we create for it and T.thailandicus a new tarsiid genus. This discovery broadens our understanding of the geographic range and morphological diversity of Miocene tarsiers and helps to put the living tarsiers into their evolutionary context. © 2013 Elsevier Ltd

New rodents (Cricetidae) from the Neogene of Curaçao and Bonaire, Dutch Antilles

Cordimus, a new genus of cricetid rodent, is described from Neogene deposits on the islands of Curaçao and Bonaire, Dutch Antilles. The genus is characterized by strongly cuspidate molars, the presence of mesolophs in most upper molars and the absence of mesolophids in lower molars. Similarities with the early cricetid Copemys from the Miocene of North America coupled with apparent derived characters shared with the subfamily Sigmodontinae suggest that Cordimus may be close to the root of the sigmodontine lineage, a possibility that remains to be tested through explicit phylogenetic analysis. Three species are recognized on the basis of size and details of molar morphology. Cordimus hooijeri sp. nov. is described from Bonaire on the basis of Holocene owl pellet material that consists of dentaries and postcranial material only. This species is presumed to be extinct, but focused surveys are needed to confirm this hypothesis. Cordimus debuisonjei sp. nov. and Cordimus raton sp. nov. are described from deposits on Tafelberg Santa Barbara in Curaçao. Although the age of these deposits is not known, they are most likely of late Pliocene or early Pleistocene age. Both are represented by numerous isolated molars and some osteological material

TGFβ1-induced leucine limitation uncovered by differential ribosome codon reading

Cancer cells modulate their metabolic networks to support cell proliferation and a higher demand of building blocks. These changes may restrict the availability of certain amino acids for protein synthesis, which can be utilized for cancer therapy. However, little is known about the amino acid demand changes occurring during aggressive and invasive stages of cancer. Recently, we developed diricore, an approach based on ribosome profiling that can uncover amino acid limitations. Here, we applied diricore to a cellular model in which epithelial breast cells respond rapidly to TGFβ1, a cytokine essential for cancer progression and metastasis, and uncovered shortage of leucine. Further analyses indicated that TGFβ1 treatment of human breast epithelial cells reduces the expression of SLC3A2, a subunit of the leucine transporter, which diminishes leucine uptake and inhibits cell proliferation. Thus, we identified a specific amino acid limitation associated with the TGFβ1 response, a vulnerability that might be associated with aggressiveness in cancer

Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)

BACKGROUND: For gastric cancer patients, surgical resection with en-bloc lymphadenectomy is the cornerstone of curative treatment. Open gastrectomy has long been the preferred surgical approach worldwide. However, this procedure is associated with considerable morbidity. Several meta-analyses have shown an advantage in short-term outcomes of laparoscopic gastrectomy compared to open procedures, with similar oncologic outcomes. However, it remains unclear whether the results of these Asian studies can be extrapolated to the Western population. In this trial from the Netherlands, patients with resectable gastric cancer will be randomized to laparoscopic or open gastrectomy. METHODS: The study is a non-blinded, multicenter, prospectively randomized controlled superiority trial. Patients (≥18 years) with histologically proven, surgically resectable (cT1-4a, N0-3b, M0) gastric adenocarcinoma and European Clinical Oncology Group performance status 0, 1 or 2 are eligible to participate in the study after obtaining informed consent. Patients (n = 210) will be included in one of the ten participating Dutch centers and are randomized to either laparoscopic or open gastrectomy. The primary outcome is postoperative hospital stay (days). Secondary outcome parameters include postoperative morbidity and mortality, oncologic outcomes, readmissions, quality of life and cost-effectiveness. DISCUSSION: In this randomized controlled trial laparoscopic and open gastrectomy are compared in patients with resectable gastric cancer. It is expected that laparoscopic gastrectomy will result in a faster recovery of the patient and a shorter hospital stay. Secondly, it is expected that laparoscopic gastrectomy will be associated with a lower postoperative morbidity, less readmissions, higher cost-effectiveness, better postoperative quality of life, but with similar mortality and oncologic outcomes, compared to open gastrectomy. The study started on 1 December 2014. Inclusion and follow-up will take 3 and 5 years respectively. Short-term results will be analyzed and published after discharge of the last randomized patient. TRIAL REGISTRATION: NCT02248519